Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$15.95 - $26.8 $3.57 Million - $6 Million
223,746 New
223,746 $3.58 Million
Q1 2023

May 15, 2023

BUY
$30.21 - $48.1 $514,627 - $819,383
17,035 New
17,035 $566,000
Q2 2022

Aug 15, 2022

SELL
$23.14 - $49.68 $497,810 - $1.07 Million
-21,513 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$27.77 - $64.4 $597,416 - $1.39 Million
21,513 New
21,513 $947,000
Q4 2021

Feb 14, 2022

SELL
$54.9 - $105.21 $2.17 Million - $4.16 Million
-39,524 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$105.0 - $178.37 $3.99 Million - $6.78 Million
38,024 Added 2534.93%
39,524 $4.17 Million
Q2 2021

Aug 16, 2021

SELL
$125.11 - $180.0 $2.94 Million - $4.23 Million
-23,500 Reduced 94.0%
1,500 $265,000
Q1 2021

May 17, 2021

BUY
$126.27 - $191.71 $3.16 Million - $4.79 Million
25,000 New
25,000 $3.34 Million
Q4 2020

Feb 16, 2021

SELL
$81.94 - $135.34 $2.61 Million - $4.3 Million
-31,795 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$73.3 - $89.48 $21.7 Million - $26.5 Million
-296,313 Reduced 90.31%
31,795 $3,000
Q2 2020

Aug 14, 2020

BUY
$48.82 - $82.53 $8.41 Million - $14.2 Million
172,247 Added 110.51%
328,108 $26.9 Million
Q1 2020

May 15, 2020

BUY
$39.1 - $62.9 $2.8 Million - $4.51 Million
71,641 Added 85.06%
155,861 $8.02 Million
Q4 2019

Feb 14, 2020

BUY
$29.79 - $43.06 $2.51 Million - $3.63 Million
84,220 New
84,220 $3.5 Million
Q2 2019

Aug 14, 2019

SELL
$25.73 - $35.79 $1.11 Million - $1.54 Million
-43,100 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$21.71 - $31.54 $881,078 - $1.28 Million
-40,584 Reduced 48.5%
43,100 $1.27 Million
Q4 2018

Feb 14, 2019

SELL
$14.95 - $24.72 $1.28 Million - $2.12 Million
-85,916 Reduced 50.66%
83,684 $1.94 Million
Q3 2018

Nov 14, 2018

BUY
$17.8 - $25.35 $3.02 Million - $4.3 Million
169,600 New
169,600 $3.3 Million

Others Institutions Holding ZLAB

About Zai Lab Ltd


  • Ticker ZLAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,908,704
  • Market Cap $2.55B
  • Description
  • Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...
More about ZLAB
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.